Clinical trials: Non-Muscle Invasive Bladder Neoplasms
NMIBC, MIBC
A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)
This was a multicenter, prospective, non-interventional, observational cohort study, and the enrolled patients were divided into four cohorts: cohort I was patients with high-risk upper tract urothelial carcinoma (UTUC) (pT3-4 or…
- Conditions
- NMIBC, MIBC, UTUC
- Trial name
- NCT06991868
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University First Hospital
Non-Muscle Invasive Bladder Carcinoma
Home-Based Outpatient Model for BCG Delivery to Reduce Undue Burden on Patients Undergoing Treatment for Non-Muscle Invasive Bladder Carcinoma
This phase I/II trial tests the feasibility of home based BCG delivery to reduce undue burden on patients undergoing treatment for non-muscle invasive bladder carcinoma.
- Trial name
- NCT07874347
- Testing
- BCG Solution, Best Practice, Cystoscopy
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Non Muscle Invasive Bladder Cancer
Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)
The purpose of this clinical trial is to obtain long-term follow-up information and status of bladder cancer for patients who received study treatment in the QUILT-2.005 study.
- Trial name
- NCT05981131
- Testing
- N803 plus Bacillus Calmette-Guerin (BCG)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- ImmunityBio, Inc.
Non-muscle-invasive Bladder Cancer
Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer
For patients with high-risk non-muscle-invasive bladder cancer (NMIBC), intravesical therapy of BCG is the standard treatment proved to reduce the risk of recurrence and progression.
- Trial name
- NCT05580354
- Testing
- BCG combined with Tislelizumab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Ruijin Hospital
Bladder Cancer, Quality of Life
Impacts and Testing of the "Multi-domains Active-living Program" in Operable Non-Muscle Invasive Bladder Cancer Patients
Among bladder cancer, the majority of them (70%) are non-muscle-invasive bladder cancer (NMIBC). The survival time is even longer in NMIBC. Patients with NMIBC receive surgery or transurethral resection of bladder tumor (TURBT).
- Trial name
- NCT05739968
- Testing
- Usual care + oncology case manager (OCM) care, Multi-domains Active-living Program (MAP) with e-health enhanced intervention + usual care + oncology case manager (OCM) care
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- National Taiwan University Hospital
Urinary Bladder Neoplasm
Laser vs. Electorsurgical Enbloc Resection of Bladder Tumours
To compare use of electrosurgical energy in doing En Bloc resection of bladder tumours against Laser Energy for En Bloc resection of bladder tumours Patients with non muscle invasive bladder cancer will be enrolled and randomized…
- Trial name
- NCT04029948
- Testing
- Laser En Bloc Resection Of bladder Tumor, Electro-surgical En Bloc Resection Of bladder Tumor
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
This pilot study is evaluating how well pembrolizumab and combination chemotherapy before surgery work for the treatment of specific types of muscle-invasive bladder cancer that have unusual appearance (variants).
- Conditions
- Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Muscle Invasive Bladder Carcinoma
- Trial name
- NCT04383743
- Testing
- Cisplatin, Doxorubicin, Methotrexate
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Washington
Non-muscle Invasive Bladder Cancer
Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder Cancer
A study to validate, in a prospective manner, the ability of the predefined Genomic Health bladder cancer assay to detect recurrence in patients undergoing surveillance for non-muscle invasive bladder cancer.
- Trial name
- NCT02969109
- Where
- United States
- Volunteers
- 417 people
- Sponsor
- Genomic Health®, Inc.
Urinary Bladder Neoplasms
The Bladder Instillation Comparison Study
To compare the efficacy of Mitomycin C vs. Gemcitabine vs. no adjuvant treatment as a single intraoperative instillation in preventing recurrence of bladder cancer.
- Trial name
- BIC (NCT02695771)
- Testing
- Mitomycin C, Gemcitabine
- Where
- 3 sites in United States
- Volunteers
- 101 people
- Sponsor
- Corewell Health West
Non-muscle Invasive Bladder Cancer
A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients
A multi-center, randomized, open-label, parallel-controlled Phase Ⅲ clinical trial to evaluate the clinical safety and efficacy of APL-1202 as a single-agent oral treatment versus intravesical instillation of Epirubicin…
- Trial name
- ASCERTAIN (NCT04736394)
- Testing
- APL-1202, Epirubicin Hydrochloride
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Jiangsu Yahong Meditech Co., Ltd aka Asieris
High-Risk Non-Muscle Invasive Bladder Cancer
A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.
In the UK 20,000 people develop urothelial bladder cancer each year with 75-80% having Non-Muscle Invasive Bladder Cancer (NMIBC).
- Trial name
- TRAIN (NCT07268339)
- Testing
- radiotherapy, BCG
- Where
- United Kingdom
- Volunteers
- 328 people
- Sponsor
- The Christie NHS Foundation Trust
Superficial Bladder Cancer
Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.
The purpose of this study is to determine whether neoadjuvant intravesical Gemcitabine is enough active in patients with a solitary, low risk superficial bladder cancer.After diagnostic urethrocystoscopy or bladder sonography…
- Trial name
- NCT00191711
- Testing
- Gemcitabine
- Where
- Italy
- Volunteers
- 43 people
- Sponsor
- Eli Lilly and Company
Urinary Bladder Neoplasms
Prospective Sample Collection for Cancer of Bladder
The goal of the Flemish Databank for Urothelial Cancer is to collect clinical and pathological data of patients treated for urothelial cancer (UC).
- Trial name
- ProCaB (NCT03973671)
- Where
- Belgium
- Volunteers
- 300 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
MRI Contrast Media Adverse Reaction, Bladder Cancer
Can VI-RADS/ADC Accurately Stage Bladder Cancer??
Vesical Imaging-Reporting And Data System (VI-RADS) is proposed for predicting muscle invasive bladder cancer (MIBC) using multi-parametric MRI. However, No validation study on VI-RADS has been reported yet.
- Conditions
- MRI Contrast Media Adverse Reaction, Bladder Cancer, Bladder Disease, Bladder Neoplasm
- Trial name
- NCT04167631
- Testing
- Multi-parametric MRI
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Mansoura University
Superficial Bladder Cancer, Lower Urinary Tract Symptoms
Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms
Baobab oil is often used in traditional medicine as antipyretic, antioxidant, anti-inflammatory, analgesic and antimicrobial. It also regenerates the epithelial tissue in a short time improving tone and elasticity.
- Trial name
- Baobab (NCT01939756)
- Testing
- Intravesical baobab oil
- Where
- 2 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Savino M. Di Stasi
Non-Muscle Invasive Bladder Cancer, Self Efficacy
The Effect of Telephone-Assisted Smoking Cessation Program in Patients Diagnosed With Non-Muscle Invasive Bladder Cancer
This study will be carried out to examine the effect of telephone-assisted smoking cessation program on self-efficacy, smoking behavior, tumor recurrence and progression in patients with non-muscle invasive bladder cancer.
- Conditions
- Non-Muscle Invasive Bladder Cancer, Self Efficacy, Smoking Behaviors, Tumor Recurrence
- Trial name
- NCT05704231
- Testing
- Behavioral: Motivational Interviewing with WhatsApp video call
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Urinary Bladder Neoplasms
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.
- Trial name
- SunRISe-2 (NCT04658862)
- Testing
- Cetrelimab, TAR-200, Cisplatin
- Where
- 290 sites in United States, Argentina and 23 more
- Volunteers
- 518 people
- Sponsor
- Janssen Research & Development, LLC
Bladder Cancer
Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer
The investigators aim to investigate a possible role for radiotherapy in good prognosis bladder cancer patients has been identified as a possible alternative to cystectomy, especially for patients non-eligible for surgery but has…
- Trial name
- NCT06310369
- Testing
- radiation therapy
- Volunteers
- 50 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Bladder Cancer
Intravesical Electromotive Mitomycin After Bacillus Calmette-Guérin Failure
Patients with urothelial high risk non-muscle invasive bladder cancer patients will be treated with intravesical electromotive drug administration/mitomycin (EMDA/MMC) after bacillus Calmette-Guerin (BCG) failure.
- Trial name
- NCT04311580
- Testing
- intravesical electromotive administration of mitomycin
- Volunteers
- 52 people
- Sponsor
- University of Rome Tor Vergata
Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v6 and v7
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer
This phase I/II trial is studying the side effects of giving paclitaxel together with radiation therapy with or without trastuzumab and to see how well it works to kill any remaining tumor cells in patients who have undergone…
- Conditions
- Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v6 and v7, Stage II Bladder Cancer AJCC v6 and v7, Stage III Bladder Cancer AJCC v6 and v7
- Trial name
- NCT00238420
- Testing
- Paclitaxel, Radiation Therapy, Trastuzumab
- Where
- 184 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)